Get the Stockscreener App
0.8311
3.81%
-0.0329
Dermata Therapeutics Inc stock is traded at $0.8311, with a volume of 67,190.
It is down -3.81% in the last 24 hours and down -25.79% over the past month.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
See More
Previous Close:
$0.864
Open:
$0.8331
24h Volume:
67,190
Relative Volume:
0.00
Market Cap:
$4.12M
Revenue:
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.1566
EPS:
-5.3059
Net Cash Flow:
$-8.30M
1W Performance:
-3.36%
1M Performance:
-25.79%
6M Performance:
-34.30%
1Y Performance:
-80.09%
1-Day Range:
$0.8163
$0.8497
1-Week Range:
$0.76
$0.9701
52-Week Range:
$0.6032
$4.66
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.8311 | 4.12M | 0 | -7.10M | -8.30M | -5.3059 |
VRTX
Vertex Pharmaceuticals Inc
|
525.74 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.64 | 83.05B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
204.18 | 81.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
874.09 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.96 | 42.42B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
After exercising options at $39.42, PTC Therapeutics (PTCT) CLO Boulding sells 192 shares. - Stock Titan
Under a trading plan, Section Six sells 2,500 PTC Therapeutics (PTCT) shares. - Stock Titan
Form S-3 Dermata Therapeutics Inc For: 9 October By Investing.com - Investing.com India
Form S-3 Dermata Therapeutics Inc For: 9 October By Investing.com - Investing.com Nigeria
CEO David Kirn sells 58,061 and 272 shares of 4D Molecular Therapeutics (FDMT) under a trading plan. - Stock Titan
At $2.18 a share, Ingmar Bruns acquires 9,727 shares in Zentalis Pharmaceuticals (ZNTL). - Stock Titan
At $1.97 a share, enGene Therapeutics (ENGN) interim medical chief bought 5,102 shares. - Stock Titan
A $15 IPO brought share purchases and preferred-stock conversions at Electra Therapeutics (ETRA). - Stock Titan
Travere Therapeutics (TVTX) CEO trades 400K shares under preset plan - Stock Titan
Halozyme (HALO) director sells nearly 19,000 shares - Stock Titan
Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Dermata Therapeutics Inc. Warrant (DRMAW) Peer Comparison – Compare with Others - Value Research
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Spyre Therapeutics (SYRE) CEO sells shares in preset plan - Stock Titan
Dermata Therapeutics Inc. Warrant (DRMAW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Nasdaq starts delisting Crinetics (NASDAQ: CRNX) shares and ends its Section 12(b) listing - Stock Titan
Dermata Therapeutics (DRMA) Drops 8.22% to $1.34 as Selling Pressure Drags Micro-Cap Biotech LowerMAMA Signal - vinanet.vn
Dermata Therapeutics (DRMA) Slides 8.22% as Shares Press Toward Key $1.27 SupportPost-Earnings Moves - dars.gov.et
Dermata launches first direct-to-consumer skincare product By Investing.com - Investing.com UK
Dermata launches first direct-to-consumer skincare product - Investing.com
Dermata (DRMA) Latest Quarter: Reported EPS Misses Expectations in the Current Update; Closing Move: Shares Move 2.90% Up for the Current SessionAnnual Report - vinanet.vn
Dermata Therapeutics (NASDAQ:DRMA) Commercial Strategy Gains Attention - kalkinemedia.com
Dermata opens preorders for Tome skincare product - Investing.com
Dermata opens preorders for Tome skincare product By Investing.com - Investing.com Canada
Dermata opens preorders for Tome skincare product By Investing.com - Investing.com Nigeria
Dermata opens preorders for Tome skincare product By Investing.com - Investing.com UK
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch - Newswire.com
Dermata (DRMA) Results Check: EPS Comes in Below Forecast in the Latest Reading; Market Response: Shares Move 2.80% Up for the Current SessionStrong Earnings Momentum - vinanet.vn
Dermata (NASDAQ: DRMA) ends Nasdaq listing for warrants - Stock Titan
Dermata Therapeutics raises $3.4 million in private placement - Investing.com
Dermata Therapeutics Announces Private Placement to Fund DTC Pivot - TipRanks
Form 8K Dermata Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Form 8K Dermata Therapeutics Inc For: 17 August By Investing.com - Investing.com Australia
Form 8K Dermata Therapeutics Inc For: 17 August By Investing.com - Investing.com Nigeria
Dermata Therapeutics raises $3.4 million in private placement By Investing.com - Investing.com Canada
Form 8K Dermata Therapeutics Inc For: 17 August By Investing.com - Investing.com India
Form 8K Dermata Therapeutics Inc For: 17 August By Investing.com - Investing.com UK
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Dermata Therapeutics Raises $3.2 Million in Private Placement; Investors Get Resale Rights - TradingView
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Weatherford Democrat
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Dermata Therapeutics raises $3.4 million in private placement By Investing.com - Investing.com UK
Dermata Therapeutics, Inc. announced that it expects to receive $3.347307 million in funding - marketscreener.com
DRMA Q2 2026 Earnings: Wider-Than-Expected Loss Despite 13.8% Share Price AdvanceGross Profit Margin - vinanet.vn
Why CoreWeave Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Sahm
DRMA|Dermata Therapeutics Inc|Price:1.370|Chg%:+0.290 - TradingKey
Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving? - webull.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dermata Therapeutics Inc Stock (DRMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs |
Feb 17 '26 |
Buy |
1.27 |
1,000 |
1,270 |
1,012 |
6.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):